… , therefore we await the results of other randomized studies with patients treated with the
combination of erlotinib plus bevacizumab in countries other than Japan. Secondly, the …

… the effects of erlotinib plus BSC on HRQoL in patients with … affected in patients treated with
erlotinib compared with patients … use were longer for patients receiving erlotinib, as illustrated …

… as first-line therapy, we should prefer chemotherapy to erlotinib; as maintenance therapy,
we should prefer erlotinib to placebo; as second/third-line therapy, we should prefer erlotinib or …

… III studies of erlotinib and docetaxel in patients with previously treated stage IIIB – IV
NSCLC. The BR.21 study17 of 150 mg/day erlotinib versus placebo recruited 731 patients with …

… of bevacizumab to erlotinib as first-line therapy in … ERLotinib studY (BEVERLY), with the
aim to test whether the addition of bevacizumab to first-line erlotinib prolonged PFS of patients …

… to erlotinib in patients with advanced NSCLC prompted this analysis to evaluate outcomes
for patients with … Presently, with the FDA approval of both first- and second-generation EGFR …

… not all patients received second-line erlotinib – in fact, only 21% of the patients assigned to
… allowed unblinding and the use of second-line erlotinib in patients only if the investigator felt …

… rather than chemotherapy [6], we found that the sequential combination of first-line erlotinib
and second-line chemotherapy conferred comparable survival benefits with the same …

… We conducted a post hoc analysis of data for patients in LUX-Lung 8 from mainland China
(n=67). Compared with erlotinib, afatinib reduced the risk of disease progression or death (…

… Erlotinib is indicated as first-line treatment for patients with non-small-cell lung cancer (NSCLC)
harboring an epidermal growth-factor–receptor (EGFR) mutation. Addition of a vascular …